Recent data showed that some postmenopausal women may be able to avoid adjuvant chemotherapy. The RxPONDER study found that postmenopausal women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one to three positive nodes and a 21-gene RS ≥ 25 (Oncotype DX) derived no further benefit from chemotherapy that was added to endocrine therapy. However, premenopausal patients with the same clinical characteristics saw a 45% relative risk reduction in invasive disease–free survival events.
Evidence suggests that chemotherapy does offer survival benefits for women aged 70 years or older with TNBC. A recent study found that older women with TNBC who received chemotherapy had significantly improved survival compared with those who were recommended to undergo chemotherapy but did not receive it.
Read more about treatment of locally advanced and inflammatory breast cancer.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Pavani Chalasani. Fast Five Quiz: Breast Cancer Myths - Medscape - Apr 20, 2021.
Comments